We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
LEO Pharma A/S, a global leader in medical dermatology and X-Chem, Inc., the global leader in DNA-encoded library (DEL) driven discovery solutions, announced today that they have entered into a research collaboration and license agreement.
HitGen announced that it has entered into a research collaboration agreement with Dorian Therapeutics, a private biotechnology company developing senoblockers, a new class of therapeutics that can rejuvenate cells and tissues.